Eyes on the target: Drug discovery’s new paradigm

If success in creating groundbreaking therapies boils down to one thing, it can be argued that it’s about picking the right target. From there cascade the modality, indication, patient population and other features that define the product, but none of it matters if the target is wrong. 

That’s not to dismiss the importance of the team, the investors, and the myriad other decisions made along the way to approval, but it is deference to the groundswell of new biology, and the ability to know what constitutes evidence worthy of the money and people-hours required to make a product...